1.69
price up icon8.33%   0.13
after-market Handel nachbörslich: 1.68 -0.01 -0.59%
loading
Schlusskurs vom Vortag:
$1.56
Offen:
$1.58
24-Stunden-Volumen:
912.36K
Relative Volume:
1.68
Marktkapitalisierung:
$63.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.56M
KGV:
-1.4444
EPS:
-1.17
Netto-Cashflow:
$-35.28M
1W Leistung:
+22.46%
1M Leistung:
+42.02%
6M Leistung:
-22.12%
1J Leistung:
-41.72%
1-Tages-Spanne:
Value
$1.58
$1.76
1-Wochen-Bereich:
Value
$1.38
$1.76
52-Wochen-Spanne:
Value
$0.8505
$4.42

Pds Biotechnology Corporation Stock (PDSB) Company Profile

Name
Firmenname
Pds Biotechnology Corporation
Name
Telefon
800-208-3343
Name
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Name
Mitarbeiter
24
Name
Twitter
@pdsbiotech
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
PDSB's Discussions on Twitter

Vergleichen Sie PDSB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PDSB
Pds Biotechnology Corporation
1.69 63.08M 0 -40.56M -35.28M -1.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-11-01 Eingeleitet B. Riley Securities Buy
2021-06-28 Eingeleitet Cantor Fitzgerald Overweight
2020-11-10 Hochstufung H.C. Wainwright Neutral → Buy
2020-05-27 Eingeleitet Alliance Global Partners Buy
2020-03-09 Eingeleitet Noble Capital Markets Outperform
2019-10-24 Eingeleitet Chardan Capital Markets Buy
Alle ansehen

Pds Biotechnology Corporation Aktie (PDSB) Neueste Nachrichten

pulisher
Jun 04, 2025

Northern Trust Corp Trims Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - Barchart.com

Jun 02, 2025
pulisher
Jun 02, 2025

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus - TradingView

Jun 02, 2025
pulisher
Jun 02, 2025

PDSB: PDS Biotechnology Releases Promising Results from Versamune HPV Studies | PDSB Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Clinical Trial Breakthrough: PDS Biotech Achieves 30-Month Survival in Advanced Head and Neck Cancer Patients - Stock Titan

Jun 02, 2025
pulisher
May 28, 2025

PDS Biotechnology files to sell 9.82M shares of common stock for holders - MSN

May 28, 2025
pulisher
May 28, 2025

PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Sh - GuruFocus

May 28, 2025
pulisher
May 27, 2025

PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDS - GuruFocus

May 27, 2025
pulisher
May 27, 2025

PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDSB Stock News - GuruFocus

May 27, 2025
pulisher
May 24, 2025

Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to “Hold” - Defense World

May 24, 2025
pulisher
May 23, 2025

PDS Biotechnology Corporation (PDSB)’s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Transcript : PDS Biotechnology CorporationSpecial Call - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Q2 EPS Estimates for PDS Biotechnology Raised by B. Riley - Defense World

May 23, 2025
pulisher
May 23, 2025

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times

May 23, 2025
pulisher
May 23, 2025

PDS Biotech reports extended survival in HPV cancer study - Investing.com Australia

May 23, 2025
pulisher
May 22, 2025

PDS Biotech reports extended survival in HPV cancer study By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

PDS Biotechnology Reports Promising Overall Survival Data for Versamune® HPV Combined with Pembrolizumab in HPV16-Positive Head and Neck Cancer - Nasdaq

May 22, 2025
pulisher
May 22, 2025

PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 21, 2025

PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential - Investing.com

May 21, 2025
pulisher
May 20, 2025

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase - The Manila Times

May 20, 2025
pulisher
May 17, 2025

PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript - MSN

May 17, 2025
pulisher
May 16, 2025

PDS Biotech outlines continued VERSATILE 003 Phase 3 expansion while advancing HPV16-positive head and neck cancer strategy - MSN

May 16, 2025
pulisher
May 15, 2025

Raymond James Financial Inc. Takes $26,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

May 15, 2025
pulisher
May 15, 2025

PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

PDS Biotechnology Reports Q1 2025 Progress and Financials - TipRanks

May 15, 2025
pulisher
May 14, 2025

PDS Biotech advances Phase 3 trial, reports Q1 financials By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

PDS Biotechnology: Q1 Earnings Snapshot - Midland Daily News

May 14, 2025
pulisher
May 14, 2025

EMV Capital portfolio company PDS Biotech advances cancer trial - Proactive Investors

May 14, 2025
pulisher
May 14, 2025

PDS Biotech advances Phase 3 trial, reports Q1 financials - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses - Investing.com

May 14, 2025
pulisher
May 14, 2025

Transcript : PDS Biotechnology Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

PDSB Advances with Phase 3 Trial for Versamune HPV Therapy | PDS - GuruFocus

May 14, 2025
pulisher
May 14, 2025

PDS Biotechnology Corporation Initiates VERSATILE-003 Phase 3 Trial and Announces Abstracts Selected for ASCO 2025 - Nasdaq

May 14, 2025
pulisher
May 14, 2025

PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update - TradingView

May 14, 2025
pulisher
May 13, 2025

PDS Biotechnology (PDSB) Expected to Announce Earnings on Wednesday - Defense World

May 13, 2025
pulisher
May 09, 2025

Pds Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 09, 2025
pulisher
May 08, 2025

PDS Biotechnology Unveils Promising Flu Vaccine Data - TipRanks

May 08, 2025
pulisher
May 08, 2025

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting - The Manila Times

May 08, 2025
pulisher
May 07, 2025

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results - TradingView

May 07, 2025
pulisher
May 07, 2025

Marshall Wace LLP Has $64,000 Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

May 07, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Acquires 76,800 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

May 07, 2025
pulisher
May 06, 2025

THE CANADIAN INTERNATIONAL TRADE TRIBUNAL TERMINATES ITS PRELIMINARY INJURY INQUIRY IN RESPECT OF TIDEWATER RENEWABLES LTD.'S COUNTERVAILING (ANTI-SUBSIDY) AND ANTI-DUMPING DUTY COMPLAINT RELATING TO I - The Globe and Mail

May 06, 2025
pulisher
May 04, 2025

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call Transcript - MSN

May 04, 2025
pulisher
May 02, 2025

PDS Biotechnology Enters $20M Securities Purchase Agreement - TipRanks

May 02, 2025

Finanzdaten der Pds Biotechnology Corporation-Aktie (PDSB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Kapitalisierung:     |  Volumen (24h):